Behavioral analogues of anxiety animal models

Research output: Contribution to journalArticle

160 Citations (Scopus)

Abstract

In the absence of fully characterized biological indexes, anxiety is at present measured as unpleasant effects reported verbally by patients. Because of the subjective nature of the syndrome, animal analogues have been difficult to design, but quests for new anxiolytics and a deeper understanding of the neurobiology of anxiety have fostered the development of several animal models. Usually, animals are exposed to exteroceptive or interoceptive stimuli which can be interpreted as capable of causing anxiety in humans. Then, the animals are observed for responses or behavioral deficits resulting from those stimuli in order to provide an index of anxiety. Behavioral responses that are reliably produced by those stimuli and that are also antagonized by anxiolytic drugs are accepted as analogues of anxiety. Exteroceptive stimuli, useful in this respect, consist of a variety of noxious treatments such as exposure to conflictsituations or unavoidable electric shock, whereas interoceptive stimuli consist of treatment with anxiogenic drugs or electrical stimulation of selected brain areas. Elicitation of unconditioned behavior or changes in the rate of conditioned (learned) responding have been employed as measures of anxiety responses following application of either exteroceptive or interoceptive stimuli. These measures, although useful in detecting anxiolytic drugs, possess several weaknesses. They suffer from difficulties in obtaining quantitative and objective data, they do not differentiate between anxiety and stress or fear, they are unable to measure further deterioration of behavior expected to occur when more potent anxiogenic stimuli are tested and they often present difficulty in differentiating direct motor effects of a number of stimuli not related to anxiety. More recently, interest in the development of other analogues of anxiety has led to the use of drug-discrimination paradigms. In this approach, interoceptive discriminative stimuli, produced by anxiogenic drugs, are used as analogues of anxiety in animals. As an example of this approach, data are reviewed showing that pentylenetetrazol, an anxiogenic drug in humans, produces interoceptive stimuli which can be readily discriminated by rats. Further, these stimuli can be easily quantified through dose-response analysis. All known anxiogenic drugs generalize to pentylenetetrazol-induced interoceptive discriminative stimuli. Similarly, other anxiety-provoking situations in humans, such as withdrawal from dependence on benzodiazepines, also generalize to the pentylenetetrazol-induced stimuli. Alternatively, all known anxiolytic drugs antagonize these stimuli with a relative potency similar to those reported clinically. The data obtained from the drug discrimination procedure are collected through automatic devices, are objective and are in a format easily amenable to quantitative statistical treatment. Moreover, the measurements are independent of response rates and are, therefore, not confounded by the motor effects of either drug or other anxiogenic treatments. The novel development in animal analogues of anxiety as indicated by the drug discrimination technique shows potential for facilitating research on the neurobiology of anxiety as well as on mechanisms underlying anxiety disorders. It also provides a novel approach for the discovery of new drugs to treat anxiety.

Original languageEnglish
Pages (from-to)1423-1441
Number of pages19
JournalNeuropharmacology
Volume22
Issue number12
DOIs
StatePublished - Dec 1983

Fingerprint

Anxiety
Animal Models
Pharmaceutical Preparations
Anti-Anxiety Agents
Pentylenetetrazole
Neurobiology
Deep Brain Stimulation
Drug Discovery
Anxiety Disorders
Benzodiazepines
Fear
Shock
Equipment and Supplies

Cite this

@article{56434435ce714b8f998db1b89b720f0e,
title = "Behavioral analogues of anxiety animal models",
abstract = "In the absence of fully characterized biological indexes, anxiety is at present measured as unpleasant effects reported verbally by patients. Because of the subjective nature of the syndrome, animal analogues have been difficult to design, but quests for new anxiolytics and a deeper understanding of the neurobiology of anxiety have fostered the development of several animal models. Usually, animals are exposed to exteroceptive or interoceptive stimuli which can be interpreted as capable of causing anxiety in humans. Then, the animals are observed for responses or behavioral deficits resulting from those stimuli in order to provide an index of anxiety. Behavioral responses that are reliably produced by those stimuli and that are also antagonized by anxiolytic drugs are accepted as analogues of anxiety. Exteroceptive stimuli, useful in this respect, consist of a variety of noxious treatments such as exposure to conflictsituations or unavoidable electric shock, whereas interoceptive stimuli consist of treatment with anxiogenic drugs or electrical stimulation of selected brain areas. Elicitation of unconditioned behavior or changes in the rate of conditioned (learned) responding have been employed as measures of anxiety responses following application of either exteroceptive or interoceptive stimuli. These measures, although useful in detecting anxiolytic drugs, possess several weaknesses. They suffer from difficulties in obtaining quantitative and objective data, they do not differentiate between anxiety and stress or fear, they are unable to measure further deterioration of behavior expected to occur when more potent anxiogenic stimuli are tested and they often present difficulty in differentiating direct motor effects of a number of stimuli not related to anxiety. More recently, interest in the development of other analogues of anxiety has led to the use of drug-discrimination paradigms. In this approach, interoceptive discriminative stimuli, produced by anxiogenic drugs, are used as analogues of anxiety in animals. As an example of this approach, data are reviewed showing that pentylenetetrazol, an anxiogenic drug in humans, produces interoceptive stimuli which can be readily discriminated by rats. Further, these stimuli can be easily quantified through dose-response analysis. All known anxiogenic drugs generalize to pentylenetetrazol-induced interoceptive discriminative stimuli. Similarly, other anxiety-provoking situations in humans, such as withdrawal from dependence on benzodiazepines, also generalize to the pentylenetetrazol-induced stimuli. Alternatively, all known anxiolytic drugs antagonize these stimuli with a relative potency similar to those reported clinically. The data obtained from the drug discrimination procedure are collected through automatic devices, are objective and are in a format easily amenable to quantitative statistical treatment. Moreover, the measurements are independent of response rates and are, therefore, not confounded by the motor effects of either drug or other anxiogenic treatments. The novel development in animal analogues of anxiety as indicated by the drug discrimination technique shows potential for facilitating research on the neurobiology of anxiety as well as on mechanisms underlying anxiety disorders. It also provides a novel approach for the discovery of new drugs to treat anxiety.",
author = "H. Lal and Emmett-Oglesby, {M. W.}",
year = "1983",
month = "12",
doi = "10.1016/0028-3908(83)90111-9",
language = "English",
volume = "22",
pages = "1423--1441",
journal = "Neuropharmacology",
issn = "0028-3908",
publisher = "Elsevier Ltd",
number = "12",

}

Behavioral analogues of anxiety animal models. / Lal, H.; Emmett-Oglesby, M. W.

In: Neuropharmacology, Vol. 22, No. 12, 12.1983, p. 1423-1441.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Behavioral analogues of anxiety animal models

AU - Lal, H.

AU - Emmett-Oglesby, M. W.

PY - 1983/12

Y1 - 1983/12

N2 - In the absence of fully characterized biological indexes, anxiety is at present measured as unpleasant effects reported verbally by patients. Because of the subjective nature of the syndrome, animal analogues have been difficult to design, but quests for new anxiolytics and a deeper understanding of the neurobiology of anxiety have fostered the development of several animal models. Usually, animals are exposed to exteroceptive or interoceptive stimuli which can be interpreted as capable of causing anxiety in humans. Then, the animals are observed for responses or behavioral deficits resulting from those stimuli in order to provide an index of anxiety. Behavioral responses that are reliably produced by those stimuli and that are also antagonized by anxiolytic drugs are accepted as analogues of anxiety. Exteroceptive stimuli, useful in this respect, consist of a variety of noxious treatments such as exposure to conflictsituations or unavoidable electric shock, whereas interoceptive stimuli consist of treatment with anxiogenic drugs or electrical stimulation of selected brain areas. Elicitation of unconditioned behavior or changes in the rate of conditioned (learned) responding have been employed as measures of anxiety responses following application of either exteroceptive or interoceptive stimuli. These measures, although useful in detecting anxiolytic drugs, possess several weaknesses. They suffer from difficulties in obtaining quantitative and objective data, they do not differentiate between anxiety and stress or fear, they are unable to measure further deterioration of behavior expected to occur when more potent anxiogenic stimuli are tested and they often present difficulty in differentiating direct motor effects of a number of stimuli not related to anxiety. More recently, interest in the development of other analogues of anxiety has led to the use of drug-discrimination paradigms. In this approach, interoceptive discriminative stimuli, produced by anxiogenic drugs, are used as analogues of anxiety in animals. As an example of this approach, data are reviewed showing that pentylenetetrazol, an anxiogenic drug in humans, produces interoceptive stimuli which can be readily discriminated by rats. Further, these stimuli can be easily quantified through dose-response analysis. All known anxiogenic drugs generalize to pentylenetetrazol-induced interoceptive discriminative stimuli. Similarly, other anxiety-provoking situations in humans, such as withdrawal from dependence on benzodiazepines, also generalize to the pentylenetetrazol-induced stimuli. Alternatively, all known anxiolytic drugs antagonize these stimuli with a relative potency similar to those reported clinically. The data obtained from the drug discrimination procedure are collected through automatic devices, are objective and are in a format easily amenable to quantitative statistical treatment. Moreover, the measurements are independent of response rates and are, therefore, not confounded by the motor effects of either drug or other anxiogenic treatments. The novel development in animal analogues of anxiety as indicated by the drug discrimination technique shows potential for facilitating research on the neurobiology of anxiety as well as on mechanisms underlying anxiety disorders. It also provides a novel approach for the discovery of new drugs to treat anxiety.

AB - In the absence of fully characterized biological indexes, anxiety is at present measured as unpleasant effects reported verbally by patients. Because of the subjective nature of the syndrome, animal analogues have been difficult to design, but quests for new anxiolytics and a deeper understanding of the neurobiology of anxiety have fostered the development of several animal models. Usually, animals are exposed to exteroceptive or interoceptive stimuli which can be interpreted as capable of causing anxiety in humans. Then, the animals are observed for responses or behavioral deficits resulting from those stimuli in order to provide an index of anxiety. Behavioral responses that are reliably produced by those stimuli and that are also antagonized by anxiolytic drugs are accepted as analogues of anxiety. Exteroceptive stimuli, useful in this respect, consist of a variety of noxious treatments such as exposure to conflictsituations or unavoidable electric shock, whereas interoceptive stimuli consist of treatment with anxiogenic drugs or electrical stimulation of selected brain areas. Elicitation of unconditioned behavior or changes in the rate of conditioned (learned) responding have been employed as measures of anxiety responses following application of either exteroceptive or interoceptive stimuli. These measures, although useful in detecting anxiolytic drugs, possess several weaknesses. They suffer from difficulties in obtaining quantitative and objective data, they do not differentiate between anxiety and stress or fear, they are unable to measure further deterioration of behavior expected to occur when more potent anxiogenic stimuli are tested and they often present difficulty in differentiating direct motor effects of a number of stimuli not related to anxiety. More recently, interest in the development of other analogues of anxiety has led to the use of drug-discrimination paradigms. In this approach, interoceptive discriminative stimuli, produced by anxiogenic drugs, are used as analogues of anxiety in animals. As an example of this approach, data are reviewed showing that pentylenetetrazol, an anxiogenic drug in humans, produces interoceptive stimuli which can be readily discriminated by rats. Further, these stimuli can be easily quantified through dose-response analysis. All known anxiogenic drugs generalize to pentylenetetrazol-induced interoceptive discriminative stimuli. Similarly, other anxiety-provoking situations in humans, such as withdrawal from dependence on benzodiazepines, also generalize to the pentylenetetrazol-induced stimuli. Alternatively, all known anxiolytic drugs antagonize these stimuli with a relative potency similar to those reported clinically. The data obtained from the drug discrimination procedure are collected through automatic devices, are objective and are in a format easily amenable to quantitative statistical treatment. Moreover, the measurements are independent of response rates and are, therefore, not confounded by the motor effects of either drug or other anxiogenic treatments. The novel development in animal analogues of anxiety as indicated by the drug discrimination technique shows potential for facilitating research on the neurobiology of anxiety as well as on mechanisms underlying anxiety disorders. It also provides a novel approach for the discovery of new drugs to treat anxiety.

UR - http://www.scopus.com/inward/record.url?scp=0020987019&partnerID=8YFLogxK

U2 - 10.1016/0028-3908(83)90111-9

DO - 10.1016/0028-3908(83)90111-9

M3 - Article

C2 - 6142426

AN - SCOPUS:0020987019

VL - 22

SP - 1423

EP - 1441

JO - Neuropharmacology

JF - Neuropharmacology

SN - 0028-3908

IS - 12

ER -